Evaluation of genotoxic risk and health status in a group of volunteers after supplementation with a novel oral formulation of Coenzyme Q10.

MARTINEZ PERAFAN, F.; EHRENHAUS MASOTTA, N.; ROJAS A.M.; TRIPODI V.P.; CARBALLO, M.A.

Asunción

Congreso; XI Congreso Latinoamericano de Mutagénesis, Carcinogénesis y Teratogénesis Ambiental; 2019

Universidad Católica de Asunción (UCA) y la Facultad de Ciencias Exactas y Naturales de la Universidad Nacional de Asunción (FACEN-UNA).

The deficiency of Coenzyme Q10 (CoQ10) is a rare disease associated with various pathologies. The treatment is the supplementation of up to 50 mg/kg/day; therefore, it is necessary to develop a safe pharmaceutical form containing high doses of CoQ10. The aim of this study was to evaluate the genotoxic safety of CoQ10 supplementation in a novel matrix (oleogel), in addition to determine the plasma concentration of coenzyme, other antioxidants and glutathione. A dose of 1000 mg/day of CoQ10 contained in an oleogel was administered to 10 healthy volunteers for 14 days. Non-simultaneously, the same dose in a commercial form (capsule) was supplied to the participants. The genotoxicity was evaluated by the cytome assay in peripheral blood lymphocytes. The plasma concentrations of the oxidative parameters were quantified by HPLC. Furthermore, the general health status of the participants was monitored through the determination of biochemical parameters. The results did not show a significant difference (p>0.05) between the frequencies of the genotoxicity biomarkers (micronuclei, buds or nucleoplasmic bridges) after supplementation with oleogels or capsules. In addition, a significant increase (p